IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain - Aix-Marseille Université
Article Dans Une Revue JOURNAL OF THORACIC ONCOLOGY Année : 2022

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami
  • Fonction : Auteur
Mark A. Socinski
  • Fonction : Auteur
Christian A. Thomas
  • Fonction : Auteur
Federico Cappuzzo
  • Fonction : Auteur
Tony S. K. Mok
  • Fonction : Auteur
Gene Finley
  • Fonction : Auteur
Joachim G. Aerts
  • Fonction : Auteur
Francisco Orlandi
  • Fonction : Auteur
Robert M. Jotte
  • Fonction : Auteur
Liza C. Villaruz
  • Fonction : Auteur
Delvys Rodriguez-Abreu
  • Fonction : Auteur
Darren Wan-Teck Lim
  • Fonction : Auteur
Shelley Coleman
  • Fonction : Auteur
Anthony Lee
  • Fonction : Auteur
Geetha Shankar
  • Fonction : Auteur
Wei Yu
  • Fonction : Auteur
Ilze Bara
  • Fonction : Auteur
Makoto Nishio
  • Fonction : Auteur

Résumé

Introduction: Final overall survival (OS) analyses are presented for EGFR mutations and liver or brain metastases subgroups in the phase 3 IMpower150 study (NCT02366143) evaluating atezolizumab plus bevacizumab plus carboplatin and paclitaxel (ABCP) or atezolizumab plus carboplatin and paclitaxel (ACP) versus bevacizumab plus carboplatin and paclitaxel (BCP). Methods: Overall, 1202 patients (intention-to-treat population) with chemotherapy-naive, metastatic, nonsquamous NSCLC were randomized to ABCP, ACP, or BCP. Patients with treated, stable brain metastases were permitted. OS was evaluated in EGFR mutations and baseline liver metastases subgroups; rate and time to development of new brain metastases were evaluated in the intention-to-treat patients. Results: At data cutoff (September 13, 2019; median followup, 39.3 mo), OS improvements were sustained with ABCP versus BCP in sensitizing EGFR mutations (all: hazard ratio [HR] = 0.60; 95% confidence interval [CI]: 0.31-1.14; previous tyrosine kinase inhibitor [TKI]: HR = 0.74; 95% CI: 0.38- 1.46) and baseline liver metastases (HR = 0.68; 95% CI: 0.45- 1.02) subgroups. ACP did not have survival benefit versus BCP in sensitizing EGFR mutations (all: HR = 1.0; 95% CI: 0.57- 1.74; previous TKI: HR = 1.22; 95% CI: 0.68-2.22) or liver metastases (HR = 1.01; 95% CI: 0.68-1.51) subgroups. Overall, 100 patients (8.3%) developed new brain metastases. Although not formally evaluated, an improvement toward delayed time to development was found with ABCP versus BCP (HR = 0.68; 95% CI: 0.39-1.19). Conclusions: This final exploratory analysis revealed OS benefits for ABCP versus BCP in patients with sensitizing EGFR mutations, including those with previous TKI failures, and with liver metastases, although these results should be interpreted with caution. The impact of ABCP on delaying the development of new brain lesions requires further investigation. (c) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Dates et versions

hal-04085339 , version 1 (28-04-2023)

Identifiants

Citer

Naoyuki Nogami, Fabrice Barlesi, Mark A. Socinski, Martin Reck, Christian A. Thomas, et al.. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (2), pp.309-323. ⟨10.1016/j.jtho.2021.09.014⟩. ⟨hal-04085339⟩
19 Consultations
0 Téléchargements

Altmetric

Partager

More